Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06763809 in mild to moderate chronic plaque psoriasis
NCT03469336Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2018
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06763809 in psoriasis, sponsored by Pfizer. Primary endpoints: Change From Baseline in Psoriatic Skin Infiltrate Thickness at 19 days, Number of Participants With Treatment-emergent Adverse Events (AEs) at 49 days and 3 more. Started Apr 2018; status: completed.
02
Drugs
PF-06763809
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03469336.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469336.